Doc,

IMO shareholders should not get too excited regards this financing; hate the dilution at 11 pennies per share but predictable given the mistake Dr G made at the 50 cent dilution price with Saunders (see my previous posts).

Unless Dr G has raised sufficient funds to pay Wayne State for conducting the Beta Site study and will take ownership of the data so he can make positive significant results public, I see no reason to get excited about Cardiogencis prospects.

The company requires significant more money to conduct the second (FDA) study; without significant results from the Beta Site study IMO another financing at half this share price is in our future.

Ante